“It's Time to Invest in Biotech in Italy”


On July 5, 2004 the annual general assembly of Assobiotec - Italian Association for the Development of Biotechnology - took place in Milan, hosted by the stock exchange. Main focus of the public part was on the growing opportunities and attractiveness offered by the arising national bioindustry for private investment.

The newly appointed president of Assobiotec, Roberto Gradnik, CEO of Serono Italia, underlines the rapid growth of the Italian biotech industry in the very last years: “However, so far the sector appears to be focused only on medical applications, while the country's knowledge resources in green and white applications still lack adequate entrepreneurial exploitation. Anyway, the existing core of new biotech companies shows a very good score in terms of product pipeline, with 16 new drugs in pre-clinical or clinical development, 6 of which with orphan drug status,” he states.
Is Italy's biotech at the turning point towards a strategic development? Asso-biotec's view is optimistic. Gradnik says: “The first step must be the creation of a suitable general context, in order to catch up the delay in terms of critical mass with respect to the major international competitors. In the European context, the UK, France and Germany already showed their determination in supporting biotech's development with specific incentives. So far, Italy hasn't enjoyed a similar framework, and the existing core of dedicated companies emerged without any support, through a harsh selection of scientific excellence peaks and entrepreneurial capabilities. But in a favourable environment the potential for the creation of new dedicated companies could be by far greater”.
Assobiotec's assembly called for a number of specific measures and provisions by the national institutions which are highly needed in order to attract private investments in the biotech industry. Among these, a clear recognition of innovation as a strategic priority and a positive attitude towards the value and protection of knowledge-based “goods” (e.g. a proper implementation of the EU directive on biotech patents); furthermore, the EU-derived rules should be enforced with full respect of the notion of single EU market. Last but not least, there should be a system of fiscal incentives for high-tech enterprises in line with the leading countries, and a steady commitment into a permanent and full enforcement of the existing measures in favour of the development of industrial research and innovation.
Via Giovanni da Procida 11
20149 Milano, Italy
Tel.: +39-2-34565308
Fax: +39-2-34565284



Milan – Everyone agrees that Italy is not Greece, but it is common wisdom that the country could also be doing better. Considering the meagre growth of the Italian economy in the last decade however, data fom the 2011 survey of...



Milan – Italian drugmaker Newron Pharmaceuticals S.p.A. and Merck Serono have broadened the scope of their 5-year-old collaboration on CNS drugs. In addition to the Parkinson’s treatment safinamide, under the terms of a new...



Milan/Berlin – Swiss-Italian biotech Philogen SpA has revoked its plan to sell a 23% stake worth EUR65.3m and go public on the Milan stock exchange this Friday. The move came after German Bayer HealthCare unexpectedly terminated...



Rome – The EUR2.5m ERC Advanced Grants are the Grammies of European science – not in the same league as a Nobel Prize, but still a lucrative honor. In the fourth round since 2007, the European Research Council awarded some a590m...



Modena/London – Researchers from Germany, Italy and the UK have identified a molecule that is key to the onset of addiction and also involved into memory formation (EMBO Journal, doi:10.1038/emboj.2010.279). According to results...



Genoa/Philadelphia — The inexpensive anti-gout drug allopurinol can counteract colorectal adenoma progression, according to data presented yesterday at the 9th Annual AACR Frontiers in Cancer Prevention Research Conference...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • MOLMED (I)0.42 EUR7.69%


  • PHOTOCURE (N)46.40 NOK-8.12%
  • VERNALIS (UK)43.00 GBP-4.44%
  • E-THERAPEUTICS (UK)11.75 GBP-4.08%


  • DIAMYD MEDICAL -B- (S)7.05 SEK67.9%
  • KARO BIO (S)38.30 SEK33.4%
  • NEWRON (CH)20.65 CHF24.8%


  • BIONOR PHARMA (N)0.47 NOK-23.0%
  • NOVOZYMES (DK)284.10 DKK-14.4%
  • WILEX (D)1.53 EUR-12.6%


  • KARO BIO (S)38.30 SEK2453.3%
  • NICOX (F)10.33 EUR470.7%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%


  • BB BIOTECH (D)46.45 EUR-80.4%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.30 EUR-70.4%

No liability assumed, Date: 23.08.2016


All Events